- Home
- HTBI vs PLRX Comparison
HTBI vs PLRX Comparison
Compare HTBI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBI
- PLRX
- Stock Information
- Founded
- HTBI 1926
- PLRX 2015
- Country
- HTBI United States
- PLRX United States
- Employees
- HTBI N/A
- PLRX N/A
- Industry
- HTBI Savings Institutions
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- HTBI Finance
- PLRX Health Care
- Exchange
- HTBI Nasdaq
- PLRX Nasdaq
- Market Cap
- HTBI 641.9M
- PLRX 641.5M
- IPO Year
- HTBI 2012
- PLRX 2020
- Fundamental
- Price
- HTBI $33.50
- PLRX $11.60
- Analyst Decision
- HTBI Buy
- PLRX Strong Buy
- Analyst Count
- HTBI 4
- PLRX 7
- Target Price
- HTBI $39.00
- PLRX $40.50
- AVG Volume (30 Days)
- HTBI 30.5K
- PLRX 544.2K
- Earning Date
- HTBI 01-27-2025
- PLRX 02-26-2025
- Dividend Yield
- HTBI 1.44%
- PLRX N/A
- EPS Growth
- HTBI 14.18
- PLRX N/A
- EPS
- HTBI 3.52
- PLRX N/A
- Revenue
- HTBI $187,440,000.00
- PLRX N/A
- Revenue This Year
- HTBI N/A
- PLRX N/A
- Revenue Next Year
- HTBI N/A
- PLRX N/A
- P/E Ratio
- HTBI $9.54
- PLRX N/A
- Revenue Growth
- HTBI 2.84
- PLRX N/A
- 52 Week Low
- HTBI $23.55
- PLRX $10.22
- 52 Week High
- HTBI $38.99
- PLRX $18.92
- Technical
- Relative Strength Index (RSI)
- HTBI 45.36
- PLRX 39.38
- Support Level
- HTBI $31.11
- PLRX $11.02
- Resistance Level
- HTBI $33.83
- PLRX $12.70
- Average True Range (ATR)
- HTBI 0.80
- PLRX 0.83
- MACD
- HTBI 0.06
- PLRX -0.16
- Stochastic Oscillator
- HTBI 73.31
- PLRX 17.93
About HTBI HomeTrust Bancshares Inc.
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.